RC
VIVO

RegentAtlantic Capital’s Meridian Bioscience Inc VIVO Stock Holding History

RegentAtlantic Capital’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-250
Closed -$4.12K – 1020
2014
Q4 		$4.12K Buy
+250
New +$4.29K ﹤0.01% 1039

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return

RegentAtlantic Capital's VIVO Position: Q1 2015 in Review

RegentAtlantic Capital sold out of Meridian Bioscience Inc (VIVO) in Q1 2015, closing a stake of 250 shares — an estimated $4.12K sold.

RegentAtlantic Capital first reported a position in VIVO in Q4 2014 and held it in 1 quarter. The position peaked at $4.12K in Q4 2014. 159 funds tracked by Wall St. Rank hold VIVO as of Q1 2015.

  • RegentAtlantic Capital reported no remaining Meridian Bioscience Inc position as of Q1 2015 after selling out during the quarter.
  • RegentAtlantic Capital sold 250 Meridian Bioscience Inc shares in Q1 2015, an estimated $4.12K.
  • RegentAtlantic Capital first reported a position in Meridian Bioscience Inc in Q4 2014 and held it in 1 quarter.
  • RegentAtlantic Capital's Meridian Bioscience Inc position peaked at $4.12K in Q4 2014.
  • 159 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2015.

Based on RegentAtlantic Capital's 13F filing for Q1 2015, filed 27 Apr 2015.